Piramal Pharma
Drug Manufacturers - Specialty & Generic · PPLPHARMA
Mid CapHealthcareDistressed / Turnaround
Peter DeYoung
CEO (Global Pharma & Executive Director) · Transformational
Company DNA
Performance-Driven
About
Piramal Pharma is a Mid Cap company in the Healthcare sector, listed on NSE as PPLPHARMA. With a market cap of ₹20K Cr and revenue of ₹9K Cr, it is currently in the Distressed / Turnaround phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Undergoing significant turnaround efforts requiring intense focus on operational KPIs and aggressive growth milestones. Its strategic mandate: The business needs to optimize its complex debt profile and streamline operational profitability following its recent structural demerger and integration phase.
FAQ
What kind of company is Piramal Pharma?
Piramal Pharma is a Mid Cap Healthcare company (PPLPHARMA) in the Distressed / Turnaround phase with a market cap of ₹20K Cr. It is classified as Performance-Driven in culture.
What is Piramal Pharma's culture and work environment like?
Piramal Pharma has a Performance-Driven culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Undergoing significant turnaround efforts requiring intense focus on operational KPIs and aggressive growth milestones.
Who leads Piramal Pharma?
Piramal Pharma is led by Peter DeYoung (CEO (Global Pharma & Executive Director)), a Transformational leader with 25 years of experience.
What are Piramal Pharma's financials?
Piramal Pharma reported revenue of ₹9K Cr in FY25 with a 5-year revenue CAGR of 11.9%. Operating margin: 7.5%. Market cap: ₹20K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleDistressed / Turnaround
Undergoing significant turnaround efforts requiring intense focus on operational KPIs and aggressive growth milestones.
Mandate
The business needs to optimize its complex debt profile and streamline operational profitability following its recent structural demerger and integration phase.
The business needs to optimize its complex debt profile and streamline operational profitability following its recent structural demerger and integration phase.
Financials
Revenue FY25₹9K Cr
PAT FY25₹91 Cr
Rev CAGR 5Y11.9%
OPM7.5%
NPM1%
ROE1.1%
ROCE5.7%
P/E—
Fwd P/E56.9
P/B—
D/E60.1
Mkt Cap₹20K Cr
Promoter54.6%
Institutional20.4%
Similar Culture
Could You Lead Piramal Pharma?
Take the Genome Benchmark →